Efficacy and Safety of Intravenous Treatment of Tuberculosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

166 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-03

Study Completion Date

2018-07-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Open-label, Randomized, Multicenter, Controlled, Parallel, Comparative Study will compare the efficacy and safety of intravenous treatment with Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment and the treatment with the oral forms of Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment for Patients With Widespread Destructive Pulmonary Tuberculosis With Bacterial Excretion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness

NCT00931736

Latent Tuberculosis Infection

COMPLETED PHASE3

Ultra Curto (Ultra Short) TB Prevention Therapy

NCT04703075

Tuberculosis

COMPLETED PHASE4

Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection

NCT00023452

Tuberculosis

COMPLETED PHASE3

A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK

NCT02836483

Pulmonary Tuberculosis

COMPLETED PHASE2

Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)

NCT07163143

Tuberculosis (TB)

NOT_YET_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There are two groups of patients with first diagnosed widespread destructive pulmonary tuberculosis with bacterial excretion. The first group receives intravenous treatment with Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment. The second group gets oral forms of Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of Tuberculosis treatment. Then both groups receive oral treatment of tuberculosis according to the known scheme.

Up to 318 participants will be randomized into this study, with 159 participants being randomized to the control arm and 159 participants being randomized to the experimental arm. It Supposed that not less than 254 participants will finish the study (about 127 participants in each arm) and their results will be included in the statistical analysis.

While the intensive phase participants of both arms will be hospitalized in the Tuberculosis Dispensary.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis, Pulmonary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group

Patients with first diagnosed widespread destructive pulmonary tuberculosis with bacterial excretion, who receive intravenous treatment with Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment. Then group receives oral treatment of tuberculosis according to the known scheme.

Isoniazid

Intervention Type DRUG

Solution for injections, 100 mg/ml, 5 ml. Participants will get the dosage according to the instruction for use.

Rifampicin

Intervention Type DRUG

Participants will get the dosage according to the instruction for use.

Ethambutol

Intervention Type DRUG

Participants will get the dosage according to the instruction for use.

Control group

Patients with first diagnosed widespread destructive pulmonary tuberculosis with bacterial excretion, who receive oral forms of Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment. Then group receives oral treatment of tuberculosis according to the known scheme.

Rifampicin

Intervention Type DRUG

Participants will get the dosage according to the instruction for use.

Isoniazid

Intervention Type DRUG

. Participants will get the dosage according to the instruction for use.

Ethambutol

Intervention Type DRUG

Participants will get the dosage according to the instruction for use.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Isoniazid

Solution for injections, 100 mg/ml, 5 ml. Participants will get the dosage according to the instruction for use.

Intervention Type DRUG

Rifampicin

Participants will get the dosage according to the instruction for use.

Intervention Type DRUG

Ethambutol

Participants will get the dosage according to the instruction for use.

Intervention Type DRUG

Rifampicin

Participants will get the dosage according to the instruction for use.

Intervention Type DRUG

Isoniazid

. Participants will get the dosage according to the instruction for use.

Intervention Type DRUG

Ethambutol

Participants will get the dosage according to the instruction for use.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bitub Rifampin, Lyophilisate for solution for infusion 600 mg. Inbutol, Solution for injections100 mg/ml, 20 ml. Rifampicin 150 mg Capsules Isoniazid, Tablets, 300mg. Ethambutol, Tablets 400 mg.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. men and women;
2. The age of 18 - 65 years inclusive;
3. Patients diagnosed with: first diagnosed pulmonary tuberculosis;
4. Patients with at least one positive result of a microbiological study of the sputum on the Mycobacterium tuberculosis (during the screening, the results of a microbiological sputum examination on an Mycobacterium tuberculosis up to 7 days old can be used);
5. Patients with radiographically and optionally CT confirmed cavity / cavities of destruction in the lungs, as well as a widespread tuberculosis process (occupying at least 2 segments of the lungs) (during the screening, the results of X-ray examination of the chest up to 7 days old can be used );
6. For women with reproductive potential - negative result of urine test for pregnancy and consent to use a reliable method of contraception before the end of the study;
7. Provided informed written consent of the patient to participate in the study;
8. The patient's ability to adequately cooperate in the research process;
9. Patients with negative analysis of GenXpert MBT / RIF (at the time of screening, analysis results not older than 7 days may be used);
10. Oral consent of the patient to stop using alcohol during the study period.

Exclusion Criteria

1. Patients who, according to the results of a sputum test using the GenXpert MBT / RIF method, are determined to be resistant to rifampicin.
2. Pregnancy, lactation;
3. Epilepsy and other diseases, which are accompanied by a tendency to convulsive seizures;
4. Severe psychosis;
5. Poliomyelitis (including in the anamnesis);
6. Diseases of the cardiovascular system, respiratory system, diabetes mellitus, impaired liver function, kidney, thyroid gland, vision, the presence of concomitant diseases or acute conditions, which, according to the researcher, do not allow the patient to participate in this study;
7. HIV infection;
8. Intolerance (including history) of any of the drugs studied;
9. Participation in any other clinical trial at the time of inclusion in this study and for the last 30 days before the date of screening.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No